Furthermore, targeting nAChR or DRD2 may be a potential therapeutic strategy to alter PD-1/PD-L1 pathway that can benefit those NSCLC patients who are refractory to immunotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.